


AMENDMENTS TO THE CLAIMS

1. (Currently amended) Compounds of General Formula 1:



General Formula 1

wherein:

Py represents pyridin-4-yl which is disubstituted in positions 2 and 6, whereby the substituent in position 2 is C₁₋₇-alkyl, aryl-C₁₋₇-alkyl, or (E)-2-aryl-ethen-1-yl, and the substituent in position 6 is hydrogen or C₁₋₇-alkyl methyl or ethyl;

X represents aryl; aryl C₁₋₇-alkyl; aryl O; aryl C₁₋₇-alkyl O; R¹-SO₂NR²; R¹-CONR²; aryl-R⁸-CONR²; R¹-NR³CONR²; R¹-NR²CO; or X and Z represent together with the carbon atom to which they are attached an exocyclic double bond which bears an aryl substituent at the thus formed methylene group;

Z represents hydrogen; in case X represents aryl or aryl C₁₋₇-alkyl Z represents hydrogen, hydroxyl, carboxyl or R⁴-NR⁵CO; in case X represents R¹-NR²CO Z represents hydrogen or C₁₋₇-alkyl; or in case X represents aryl or aryl C₁₋₇-alkyl and n represents the number 0, Z represents hydrogen, hydroxyl, carboxyl, R⁴-NR⁵CO, aryl or aryl C₁₋₇-alkyl;

Y represents -C(R⁶)(R⁷)(CH₂)_m- or -(CH₂)_mC(R⁶)(R⁷)-;

m represents the numbers 1 or 2;

n represents the numbers 0 or 1;

R¹ represents aryl or aryl-C₁₋₇-alkyl;

R² represents hydrogen; C₁₋₇-alkyl; 2-hydroxyethyl; aryl-C₁₋₇-alkyl; or a saturated carbocyclic ring;

R³ represents hydrogen or C₁₋₇-alkyl;

R⁴ represents hydrogen; C₁₋₇-alkyl; aryl; aryl-C₁₋₇-alkyl; or forms together with R⁵ a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R⁴ and R⁵ are attached as ring atom;

R⁵ represents hydrogen; C₁₋₇-alkyl; 2-hydroxyethyl; or forms together with R⁴ a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R⁴ and R⁵ are attached as ring atom;

R⁶ represents hydrogen; C₁₋₇-alkyl; aryl; aryl-C₁₋₇-alkyl; or forms together with R⁷ a saturated carbocyclic ring including the carbon atom to which R⁶ and R⁷ are attached as ring atom;


R⁷ represents hydrogen; methyl; or forms together with R⁶ a saturated carbocyclic ring including the carbon atom to which R⁶ and R⁷ are attached as ring atom, and

R⁸ represents a saturated carbocyclic ring;

~~or optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, and mixtures of diastereomeric racemates, of said compound; or pharmaceutically acceptable salts, solvent complexes, or morphological forms, of said compound.~~

in free or pharmaceutically acceptable salt form.

2. (Currently amended) A compound of General Formula 2 according to claim 1:



General Formula 2

wherein:

Py represents pyridin-4-yl which is disubstituted in positions 2 and 6, whereby the substituent in position 2 is C₁₋₇-alkyl or aryl-C₁₋₇-alkyl and the substituent in position 6 is methyl or ethyl;

X represents aryl; aryl-C₁₋₇-alkyl; aryl-O-; aryl-C₁₋₇-alkyl-O-; R¹-SO₂NR²-; R¹-CONR²-; aryl-R⁸-CONR²-; or R¹-NR³CONR²-; or R¹-NR²CO-

Z represents hydrogen; ~~in case X represents aryl or aryl-C₁₋₇-alkyl and n represents the number 1 Z represents hydrogen, hydroxyl or R⁴-NR⁵CO-~~

n represents the numbers 0 or 1;

R¹ represents aryl or aryl-C₁₋₇-alkyl;

R² represents hydrogen; C₁₋₇-alkyl; 2-hydroxyethyl; aryl-C₁₋₇-alkyl; or a saturated carbocyclic ring;


R³ represents hydrogen or C₁₋₇-alkyl;

R⁴ represents hydrogen; C₁₋₇-alkyl; aryl; aryl-C₁₋₇-alkyl; or forms together with R⁵ a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R⁴ and R⁵ are attached as ring atom;

R⁵ represents hydrogen; C₁₋₇-alkyl; 2-hydroxyethyl; or forms together with R⁴ a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R⁴ and R⁵ are attached as ring atom; and


R⁸ represents a saturated carbocyclic ring.

- 3 (Withdrawn-currently amended) The A-compound of General Formula 3 according to claim 1:




wherein n, Y, Z and Py have the meaning given in General Formula 1.

- 4 (Withdrawn-currently amended) The A-compound of General Formula 4 according to claim 1:




wherein n, Y, Z and Py have the meaning given in General Formula 1.

- 5 (Currently amended) The A-compound of General Formula 5 according to claim 1:




wherein R², Y, n and Py have the meaning given in General Formula 1.

- 6 (Withdrawn-currently amended) The A-compound of General Formula 6 according to claim 1:



wherein R⁴, R⁵, Y, n and Py have the meaning given in General Formula 1.


- 7 (Withdrawn-currently amended) The A-compound of General Formula 7 according to claim 1:



General Formula 7

wherein R¹, R², Z, Y, n and Z have the meaning given in General Formula 1.


- 8 (Currently amended) The A-compound of General Formula 8 according to claim 1:



General Formula 8

wherein R¹, R², n, Y and Py have the meaning given in General Formula 1.


- 9 (Currently amended) The A-compound of General Formula 9 according to claim 1:



General Formula 9


wherein X, Y, Z, n and Py have the meaning given in General Formula 1.

- 10 (Currently amended) The A-compound of General Formula 10 according to claim 1:




wherein X, Y, Z, n and Py have the meaning given in General Formula 1.

11 (Currently amended) The A-compound of General Formula 11 according to claim 1:




wherein X, Y, Z, n and Py have the meaning given in General Formula 1.

12 (Withdrawn-currently amended) The A-compound of General Formula 12 according to claim 1:




wherein n, Z and Py have the meaning given in General Formula 2.

13 (Withdrawn-currently amended) The A-compound of General Formula 13 according to claim 1:




wherein n, Z and Py have the meaning given in General Formula 2.

14. (Currently amended) The A compound of General Formula 14 according to claim 1:




wherein R², n and Py have the meaning given in General Formula 2.

15. (Withdrawn-currently amended) The A-compound of General Formula 15 according to claim 1:




wherein R⁴, R⁵, n and Py have the meaning given in General Formula 2.

16. (Withdrawn-currently amended) The A-compound of General Formula 13 according to claim 1:



wherein R¹, R², Z, n and Z have the meaning given in General Formula 2.


17. (Currently amended) The A compound of General Formula 17 according to claim 1:



General Formula 17

wherein R¹, R², n and Py have the meaning given in General Formula 2.


18. (Currently amended) The A compound of General Formula 18 according to claim 1:



General Formula 18

wherein X, Z and Py have the meaning given in General Formula 2.


19. (Currently amended) The A compound of General Formula 19 according to claim 1:



General Formula 19

wherein X, Z and n have the meaning given in General Formula 2.


20. (Currently amended) The A compound of General Formula 20 according to claim 1:



General Formula 20

wherein X, Z and n have the meaning given in General Formula 2.


21. (Currently amended) The A compound of General Formula 21 according to claim 1:



General Formula 21

wherein R¹ and R² have the meaning given in General Formula 2.


22. (Currently amended) The A compound of General Formula 22 according to claim 1:



General Formula 22

wherein R² and n have the meaning given in General Formula 2.


23 (Withdrawn-currently amended) The A compound of General Formula 23 according to claim 1:



General Formula 23


wherein Z has the meaning given in General Formula 2.

24 (Withdrawn-currently amended) The A compound of General Formula 24 according to claim 1:



wherein Z has the meaning given in General Formula 2.

25. (Currently amended) A compound of the General Formula 25



wherein:

Py represents pyridin-4-yl which is disubstituted in positions 2 and 6, whereby the substituent in position 2 is C_{1.7}-alkyl, aryl-C_{1.7}-alkyl, or (E)-2-aryl-ethen-1-yl, and the substituent in position 6 is hydrogen or C_{1.7}-alkyl methyl or ethyl;

X represents aryl; aryl-O-; aryl-C_{1.7}-alkyl ; R¹-SO₂NR²-; R¹-CONR²-; or R¹-NR³CONR²-; R¹-NR²CO-; or X and Z represent together with the carbon atom to which they are attached an exocyclic double bond which bears an aryl substituent at the thus formed methylene group;

Y represents -C(R⁴)(R⁵)(CH₂)_m- or -(CH₂)_mC(R⁴)(R⁵)-;

Z represents hydrogen; in case X represents aryl or aryl-C_{1.7}-alkyl Z represents hydrogen, hydroxyl, carboxyl, R¹-NR²CO-; or in case X represents aryl or aryl-C_{1.7}-alkyl and n represents the number 0, Z represents hydrogen, hydroxyl, carboxyl, R¹-NR²CO-, aryl, aryl-C_{1.7}-alkyl;

n represents the numbers 0 or 1;

m represents the numbers 1 or 2;

R¹ represents aryl; C_{1.7}-alkyl; aryl-C_{1.7}-alkyl; or a saturated carbocyclic ring;

R^2 and R^3 represent independently hydrogen; C₁₋₇-alkyl; aryl-C₁₋₇-alkyl; or a saturated carbocyclic ring;

R^4 represents hydrogen; C₁₋₇-alkyl; aryl; aryl-C₁₋₇-alkyl; or forms together with R^5 a saturated carboyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atom; and R^5 represents hydrogen; methyl; or forms together with R^4 a saturated carboyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atom; or configurational isomers, optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, and mixtures of diastereomeric racemates; or pharmaceutically acceptable salts, solvent complexes, or morphological forms, of said compound.

in free or pharmaceutically acceptable salt form.

26. (Currently amended) A compound selected from the group consisting of:

~~+ [2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2,6-dimethyl-pyridin-4-yl)-urea;~~

~~+ [2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl]-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;~~

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-*N*-propyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-*N*-propyl-benzenesulfonamide;

~~+ (2,6-Dimethyl-pyridin-4-yl)-3-[2-(3,3-diphenyl-pyrrolidin-1-yl)-ethyl]-urea;~~

~~+ [2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2,6-dimethyl-pyridin-4-yl)-urea;~~

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-fluoro-benzenesulfonamide;

~~+ (2-[3-[2-Methyl-6-((E)-styryl)-pyridin-4-yl]-ureido)-ethyl]-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;~~

N-Ethyl-4-methoxy-*N*-(1-{2-[3-(2-methyl-6-phenethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

~~1-[2-[3-(2-Methyl-6-propyl-pyridin-4-yl)-ureido]-ethyl]-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;~~

~~1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2-methyl-6-propyl-pyridin-4-yl)-urea;~~

N-Ethyl-4-methoxy-*N*-(1-{2-[3-(2-methyl-6-propyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

~~1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2-ethyl-6-methyl-pyridin-4-yl)-urea;~~

N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-benzenesulfonamide;

~~1-[2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl]-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;~~

~~1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-phenethyl-pyridin-4-yl)-urea;~~

~~1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-[2-(4-fluoro-phenyl)-ethyl]-pyridin-4-yl)-urea;~~

~~1-[2-[3-(2-Methyl-6-phenethyl-pyridin-4-yl)-ureido]-ethyl]-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;~~

2-(4-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-acetamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-benzenesulfonamide;

~~1-[2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl]-4-phenyl-piperidine-4-carboxylic acid benzyl-(2-hydroxy-ethyl)-amide;~~

~~1-[2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl]-4-phenyl-piperidine-4-carboxylic acid benzyl-(2-hydroxy-ethyl)-amide;~~

N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-benzenesulfonamide;

~~1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2,6-diethyl-pyridin-4-yl)-urea;~~

N-(1-{2-[3-(2,6-Diethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-benzenesulfonamide;

N-(1-{2-[3-(2,6-Diethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-fluoro-benzenesulfonamide;

N-(1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-*N*-propylbenzenesulfonamide;

4-Bromo-*N*-ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-(1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-*N*-propylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-ethyl-*N*-methylbenzenesulfonamide;

N-(4-[(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-sulfamoyl]-phenyl)-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-isopropoxy-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4,*N*-dimethylbenzenesulfonamide;

4-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methylbenzenesulfonamide;

3,4-Dichloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-4-trifluoromethylbenzenesulfonamide;

5-Chloro-thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide;

2,5-Dichloro-thiophene-3-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-fluorobenzenesulfonamide;

- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-fluoro-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2,4-difluoro-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3,4-difluoro-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2,6-difluoro-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4,*N*-diethyl-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-isopropoxy-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methyl-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-methyl-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methyl-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-2,3,6-trimethyl-benzenesulfonamide;
- 4-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide;
- 3-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide;
- 2-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide;
- 3,4-Dichloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-trifluoromethyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-trifluoromethyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-trifluoromethyl-benzenesulfonamide;

Thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

5-Chloro-thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

2,5-Dichloro-thiophene-3-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2,5-dimethoxy-benzenesulfonamide;

5-Bromo-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methoxy-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methoxy-4-methyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3,4-dimethoxy-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3,4-dimethoxy-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-methoxy-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-fluoro-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,4-difluoro-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,6-difluoro-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-ethyl-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-isopropoxy-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methyl-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methyl-benzenesulfonamide;

4-Chloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

3-Chloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

2-Chloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

3,4-Dichloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-trifluoromethyl-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-trifluoromethyl-benzenesulfonamide;

5-Chloro-thiophene-2-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

2,5-Dichloro-thiophene-3-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,5-dimethoxy-benzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4-methyl-benzenesulfonamide;

N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4-methyl-benzenesulfonamide;

N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-dimethoxy-benzenesulfonamide;

N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy-benzenesulfonamide;

1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide;

2-(4-Chloro-phenyl)-*N*-ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-isobutyramide;

2-(3,4-Dichloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-acetamide;

2-(4-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-isobutyramide;

1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

1-Phenyl-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

2-(4-Chloro-phenyl)-*N*-ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-acetamide;

2-(4-Chloro-phenyl)-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-isobutyramide;

2-(4-Chloro-phenyl)-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-acetamide;

1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

1-Phenyl-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methoxybenzenesulfonamide.

27. (Previously presented) A compound selected from the group consisting of:

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-(4-methoxy-phenyl)-acetamide;

~~4-Ethyl-1-[2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl]-piperidine-4-carboxylic acid benzyl-(2-hydroxy-ethyl)-amide;~~

~~1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-ethyl-6-methyl-pyridin-4-yl)-urea;~~

~~1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2,6-diethyl-pyridin-4-yl)-urea;~~

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-dimethoxy-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4,*N*-dimethylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-fluoro-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-fluoro-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,4-difluoro-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-difluoro-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,6-difluoro-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,*N*-dimethylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,*N*-dimethylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-2,3,6,*N*-tetramethylbenzenesulfonamide;

3-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methylbenzenesulfonamide;

2-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methylbenzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-3-trifluoromethylbenzenesulfonamide;

Thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-fluorobenzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-difluorobenzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methylbenzenesulfonamide;

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-trifluoromethylbenzenesulfonamide;

Thiophene-2-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

2-(3,4-Dichloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-acetamide;

1-Phenyl-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide;

1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide;

2-(4-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-(4-fluoro-phenyl)-*N*-methyl-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-2-phenyl-acetamide;

2-(3-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-acetamide;

2-(2-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(2-methoxy-phenyl)-acetamide;

1-Phenyl-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-phenyl-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(4-methoxy-phenyl)-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-benzamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3,4-dimethoxy-benzamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-fluoro-benzamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(3-methoxy-phenyl)-acetamide;

2-(3,4-Dimethoxy-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-thiophen-2-yl-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(4-fluoro-phenyl)-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzamide;

1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-phenyl-acetamide;

1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide.

28. (Currently amended) A pharmaceutical composition containing a compound of any one of claims ~~4 to 25, 26, or 27~~ 2, 14, 17-22 or 25-27 and pharmaceutically acceptable carrier materials and adjuvants.

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

32. (Withdrawn) The method of treating a patient suffering from a disorder associated with a dysregulation of urotensin II or urotensin II receptors, or disorders associated with vascular or myocardial dysfunction, selected from the group consisting of hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, Subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases,

cirrhosis, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, and pulmonary fibrosis, said method comprising administering the pharmaceutical composition according to claim 28.

33. (Withdrawn) The method of claim 32, further comprising administering an additional pharmacologically active compound.

34. (Withdrawn) The method of claim 33, wherein said additional pharmacologically active compound is selected from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasopressin antagonists, betaadrenergic antagonists, alpha-adrenergic antagonists, vasopressin antagonists, TNFalpha antagonists, and peroxisome proliferator activator receptor modulators.

35. (Withdrawn) A method of treating a patient suffering from a disorder selected from the group consisting of restenosis after balloon or stent angioplasty, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addiction, schizophrenia, Alzheimer's disease, anxiety, obsessive-compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, and neurodegenerative diseases, said method comprising administering the pharmaceutical composition of claim 28.

36. (Withdrawn) The method of claim 35, further comprising administering an additional pharmacologically active compound.

37. (Withdrawn) The method of claim 36, wherein said additional pharmacologically active compound is selected from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasopressin antagonists, betaadrenergic

antagonists, alpha-adrenergic antagonists, vasopressin antagonists, TNFalpha antagonists, and peroxisome proliferator activator receptor modulators.